TFX:NYE-Teleflex Incorporated (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 135.66

Change

+2.64 (+1.98)%

Market Cap

USD 5.79B

Volume

0.69M

Analyst Target

USD 426.10
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, the measurement of blood pressure, and the collection of blood samples. The company also offers interventional products, including various coronary catheters, structural heart support devices, peripheral intervention products, and mechanical circulatory support platform; and Arrow branded intra-aortic balloon pumps and catheters, Guideliner, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway, pain management, and hemostatic products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligating clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology, as well as bladder management services; and OEM products, which includes the TFX Medical OEM, TFX OEM, Deknatel, and HPC Medical brands. It serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-24 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

+2.13 (+1.05%)

USD 57.94B
ALC Alcon AG

+0.98 (+1.05%)

USD 44.32B
RMD ResMed Inc

+21.66 (+10.10%)

USD 31.43B
BAX Baxter International Inc

+0.81 (+2.74%)

USD 14.28B
SOLV Solventum Corp.

+1.63 (+2.47%)

USD 11.45B
AVTR Avantor Inc

+0.03 (+0.19%)

USD 10.37B
ATR AptarGroup Inc

+3.41 (+2.30%)

USD 9.51B
STVN Stevanato Group SpA

+0.08 (+0.37%)

USD 5.98B
BLCO Bausch + Lomb Corp

+1.15 (+9.03%)

USD 4.29B
WRBY Warby Parker Inc

+0.92 (+6.17%)

USD 1.79B

ETFs Containing TFX

IJR iShares Core S&P Small-Ca.. 0.00 % 0.07 %

+1.99 (+3.87%)

USD 70.99B
IJS iShares S&P Small-Cap 600.. 0.00 % 0.25 %

+1.94 (+3.87%)

USD 5.59B
QRH:CA 0.00 % 1.20 %

N/A

N/A
SPSM SPDR® Portfolio S&P 600 .. 0.00 % 0.06 %

+0.74 (+3.87%)

USD 9.96B
SAA ProShares Ultra SmallCap6.. 0.00 % 0.95 %

+0.70 (+3.87%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.78% 26% F 10% F
Dividend Return 0.19% 40% F 5% F
Total Return -23.59% 26% F 10% F
Trailing 12 Months  
Capital Gain -34.37% 16% F 9% A-
Dividend Return 0.66% 56% F 11% F
Total Return -33.71% 21% F 9% A-
Trailing 5 Years  
Capital Gain -59.91% 20% F 6% D-
Dividend Return 2.11% 33% F 4% F
Total Return -57.80% 20% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain -13.29% 16% F 5% F
Dividend Return -12.84% 16% F 4% F
Total Return 0.45% 44% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 17.61% 74% C 58% F
Risk Adjusted Return -72.93% 11% F 2% F
Market Capitalization 5.79B 47% F 81% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector